Trials / Not Yet Recruiting
Not Yet RecruitingNCT07226466
Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates the effects of brain radiotherapy on cognitive function by evaluating plasma biomarkers and apolipoprotein E (APOE) genotype in patients with primary or metastatic brain tumors. Standard brain radiotherapy is known to impact cognitive outcomes, yet the underlying biological mechanisms remain unclear.
Detailed description
PRIMARY OBJECTIVES: 1. Assess plasma biomarkers for Aβ, GFAP, phospho Tau, and NfL pre- and post-radiotherapy. 2. Determine APOE genotype. 3. Evaluate neuropsychiatric testing aligned with standard of care brain MRIs and serum markers. 4. Measure brain morphometrics pre- and post-radiotherapy with standard of care brain MRIs. SECONDARY OBJECTIVES: 1\. Measure patient-reported quality of life changes pre- and post-radiotherapy using a standard University of California, San Francisco (UCSF) -approved questionnaire. OUTLINE: This is a single-arm, non-randomized, open-label pilot study. Participants will be study duration spans 12 months post-brain radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Blood sample | Blood sample will be collected |
| PROCEDURE | Brain magnetic resonance imaging (MRI) | Brain MRI will be performed during the course of data collection |
| PROCEDURE | Brain Health Assessment | Brain Health Assessment will be performed during the course of data collection |
| RADIATION | Quality of Life (QoL) Questionnaire | QoL questionnaire will be given to participants during the course of data collection |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2028-05-31
- Completion
- 2028-05-31
- First posted
- 2025-11-10
- Last updated
- 2025-11-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07226466. Inclusion in this directory is not an endorsement.